<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02853045</url>
  </required_header>
  <id_info>
    <org_study_id>1408032</org_study_id>
    <secondary_id>2014-001404-22</secondary_id>
    <nct_id>NCT02853045</nct_id>
  </id_info>
  <brief_title>Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients</brief_title>
  <acronym>PRINGEN</acronym>
  <official_title>Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite a large diffusion for generic anti-hypertensive, they are not currently used.

      Clinical validation studies could be better to convince users and prescribers than
      pharmacologic validation only.

      A pragmatic study to evaluate generic anti-hypertensive efficacy is proposed. It takes place
      in real conditions of care for hypertensive patients, for a manometer control criteria.

      The aim of the study is to test the hypothesis of non-inferiority for generic
      anti-hypertensive for blood pressure control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      List of drugs : ALDACTONE, FLUMACH, SPIROCTAN, SPIRONONE, FLUDEX, INDATEN, LASILIX,
      TENSTATEN, ALDACTAZINE, PRINACTIZIDE, SPIROCTAZINE, MODURETIC, AVLOCARDYL, HEMIPRALON,
      STHASIN, BETATOP, TENORMINE, CELECTOL, DETENSIEL, FELSAN, KERLONE, RAGON, RONALOL, LOPRESSOR,
      SELOKEN, NEBILOX, TEMERIT, NEVEROL, SECTRAL, ACUITEL, KOREC, BRIEM, CIBACENE, COVERSYL,
      CAPTOLANE, LOPRIL, FOZITEC, ODRIK, GOPTEN, PRINIVIL, ZESTRIL, RENITEC, TEOULA, ZOFENIL,
      TRIATEC, KENOMON, ADALATE, CHRONOADALATE, AMLOR, BAYPRESS, DELTAZEN, DILRENE, DIACOR, MONO
      TILDIEM, FLODIL, IPERTEN, ISOPTINE, LERCAN, ZANIDIP, LEDELCARBERDIPE, LENIBERCARDIPE,
      DIBERLEPIDINE, XILERMIS, APROVEL, CRISARTERS, IFIRMASTA, FLUPPE, ZELMIRB, ATACAND, KENZEN,
      KARBIS, COZAAR, LOBERASNAT, LOTANBERSAR, MICARDIS, PRITOR, TOLURA, ZANACODAR, DINORTES,
      MIRPRESOC, NISIS, TAREG, CUENCA, TIFIVAL, VAGRECOR, VAMADRID, HYPERIUM, PHYSIOTENS,
      BIPRETERAX, PRETERAX, LODOZ, WYTENS, ACUILIX, KORETIC, BRIAZIDE, CIBADREX, CAPTEA, ECAZIDE,
      CORENITEC, ENALAVIS, ENALURETIC, COTRIATEC, RADOUCHE, FOZIRETIC, PRINZIDE, ZESTORETIC,
      COAPROVEL, IFIRMACOMBI, COCRISARTERS, COKENZEN, HYTACAND, COANHYVA, COHESAN , COTAREG,
      NISISCO, FORTZAAR, HYZAAR, MICARDISPLUS, PRITORPLUS, MARESSI, TOLUCOMBI, TENORDATE, BETA
      ADALATE
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of systolic blood pressure</measure>
    <time_frame>for 24 hours</time_frame>
    <description>with holter (ambulatory)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of side effects</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>number of side effects per patient with a questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>period with drug (trade name) then period with generic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period of 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>period with generic then period with drug (trade name)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period of 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>period with drug (trade name) then period with generic</intervention_name>
    <description>The list of drugs is detailed in the &quot;study description&quot;</description>
    <arm_group_label>period with drug (trade name) then period with generic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>period with generic then period with drug (trade name)</intervention_name>
    <description>The list of drugs is detailed in the &quot;study description&quot;</description>
    <arm_group_label>period with generic then period with drug (trade name)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypertensive patient known and treated taking at least two antihypertensive

          -  Anti-hypertension treatment available in generic form

          -  Absence of changes in the anti-hypertension treatment during the previous 3 months

        Exclusion Criteria:

          -  Patients on dialysis

          -  Patients with cardiac arrhythmia

          -  Patient refusing ambulatory blood pressure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe MARIAT, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe MARIAT, MD PhD</last_name>
    <phone>(0)477828739</phone>
    <phone_ext>+33</phone_ext>
    <email>christophe.mariat@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine LABRUYERE, CRA</last_name>
    <phone>(0)477120469</phone>
    <phone_ext>+33</phone_ext>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH d'ANNONAY</name>
      <address>
        <city>Annonay</city>
        <zip>07100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne FAVRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de FEURS</name>
      <address>
        <city>Feurs</city>
        <zip>42110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georges KRUNZYNSKI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de FIRMINY</name>
      <address>
        <city>Firminy</city>
        <zip>42700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel COMBIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frederic CHOMETON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH du PUY EN VELAY</name>
      <address>
        <city>Le Puy En Velay</city>
        <zip>43000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc BOUILLER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de MONTBRISON</name>
      <address>
        <city>Montbrison</city>
        <zip>42600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rene RICHARD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de ROANNE</name>
      <address>
        <city>Roanne</city>
        <zip>42300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier DE SAUNIERES, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de SAINT-CHAMOND</name>
      <address>
        <city>Saint-chamond</city>
        <zip>42400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck FONTANEY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe MARIAT, MD PhD</last_name>
      <phone>(0)477828739</phone>
      <phone_ext>+33</phone_ext>
      <email>christophe.mariat@chu-st-etienne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Carine LABRUYERE, CRA</last_name>
      <phone>(0)477120469</phone>
      <phone_ext>+33</phone_ext>
      <email>carine.labruyere@chu-st-etienne.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Damien THIBAUDIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriana DINIC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge CHARMION, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

